Cargando…

Key contribution of eIF4H-mediated translational control in tumor promotion

Dysregulated expression of translation initiation factors has been associated with carcinogenesis, but underlying mechanisms remains to be fully understood. Here we show that eIF4H (eukaryotic translation initiation factor 4H), an activator of the RNA helicase eIF4A, is overexpressed in lung carcino...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaysse, Charlotte, Philippe, Céline, Martineau, Yvan, Quelen, Cathy, Hieblot, Corinne, Renaud, Claire, Nicaise, Yvan, Desquesnes, Aurore, Pannese, Maria, Filleron, Thomas, Escourrou, Ghislaine, Lawson, Malcolm, Rintoul, Robert C., Delisle, Marie Bernadette, Pyronnet, Stéphane, Brousset, Pierre, Prats, Hervé, Touriol, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741870/
https://www.ncbi.nlm.nih.gov/pubmed/26498689
_version_ 1782414088899395584
author Vaysse, Charlotte
Philippe, Céline
Martineau, Yvan
Quelen, Cathy
Hieblot, Corinne
Renaud, Claire
Nicaise, Yvan
Desquesnes, Aurore
Pannese, Maria
Filleron, Thomas
Escourrou, Ghislaine
Lawson, Malcolm
Rintoul, Robert C.
Delisle, Marie Bernadette
Pyronnet, Stéphane
Brousset, Pierre
Prats, Hervé
Touriol, Christian
author_facet Vaysse, Charlotte
Philippe, Céline
Martineau, Yvan
Quelen, Cathy
Hieblot, Corinne
Renaud, Claire
Nicaise, Yvan
Desquesnes, Aurore
Pannese, Maria
Filleron, Thomas
Escourrou, Ghislaine
Lawson, Malcolm
Rintoul, Robert C.
Delisle, Marie Bernadette
Pyronnet, Stéphane
Brousset, Pierre
Prats, Hervé
Touriol, Christian
author_sort Vaysse, Charlotte
collection PubMed
description Dysregulated expression of translation initiation factors has been associated with carcinogenesis, but underlying mechanisms remains to be fully understood. Here we show that eIF4H (eukaryotic translation initiation factor 4H), an activator of the RNA helicase eIF4A, is overexpressed in lung carcinomas and predictive of response to chemotherapy. In lung cancer cells, depletion of eIF4H enhances sensitization to chemotherapy, decreases cell migration and inhibits tumor growth in vivo, in association with reduced translation of mRNA encoding cell-proliferation (c-Myc, cyclin D1) angiogenic (FGF-2) and anti-apoptotic factors (CIAP-1, BCL-xL). Conversely, each isoform of eIF4H acts as an oncogene in NIH3T3 cells by stimulating transformation, invasion, tumor growth and resistance to drug-induced apoptosis together with increased translation of IRES-containing or structured 5′UTR mRNAs. These results demonstrate that eIF4H plays a crucial role in translational control and can promote cellular transformation by preferentially regulating the translation of potent growth and survival factor mRNAs, indicating that eIF4H is a promising new molecular target for cancer therapy.
format Online
Article
Text
id pubmed-4741870
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-47418702016-03-23 Key contribution of eIF4H-mediated translational control in tumor promotion Vaysse, Charlotte Philippe, Céline Martineau, Yvan Quelen, Cathy Hieblot, Corinne Renaud, Claire Nicaise, Yvan Desquesnes, Aurore Pannese, Maria Filleron, Thomas Escourrou, Ghislaine Lawson, Malcolm Rintoul, Robert C. Delisle, Marie Bernadette Pyronnet, Stéphane Brousset, Pierre Prats, Hervé Touriol, Christian Oncotarget Research Paper Dysregulated expression of translation initiation factors has been associated with carcinogenesis, but underlying mechanisms remains to be fully understood. Here we show that eIF4H (eukaryotic translation initiation factor 4H), an activator of the RNA helicase eIF4A, is overexpressed in lung carcinomas and predictive of response to chemotherapy. In lung cancer cells, depletion of eIF4H enhances sensitization to chemotherapy, decreases cell migration and inhibits tumor growth in vivo, in association with reduced translation of mRNA encoding cell-proliferation (c-Myc, cyclin D1) angiogenic (FGF-2) and anti-apoptotic factors (CIAP-1, BCL-xL). Conversely, each isoform of eIF4H acts as an oncogene in NIH3T3 cells by stimulating transformation, invasion, tumor growth and resistance to drug-induced apoptosis together with increased translation of IRES-containing or structured 5′UTR mRNAs. These results demonstrate that eIF4H plays a crucial role in translational control and can promote cellular transformation by preferentially regulating the translation of potent growth and survival factor mRNAs, indicating that eIF4H is a promising new molecular target for cancer therapy. Impact Journals LLC 2015-10-15 /pmc/articles/PMC4741870/ /pubmed/26498689 Text en Copyright: © 2015 Vaysse et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Vaysse, Charlotte
Philippe, Céline
Martineau, Yvan
Quelen, Cathy
Hieblot, Corinne
Renaud, Claire
Nicaise, Yvan
Desquesnes, Aurore
Pannese, Maria
Filleron, Thomas
Escourrou, Ghislaine
Lawson, Malcolm
Rintoul, Robert C.
Delisle, Marie Bernadette
Pyronnet, Stéphane
Brousset, Pierre
Prats, Hervé
Touriol, Christian
Key contribution of eIF4H-mediated translational control in tumor promotion
title Key contribution of eIF4H-mediated translational control in tumor promotion
title_full Key contribution of eIF4H-mediated translational control in tumor promotion
title_fullStr Key contribution of eIF4H-mediated translational control in tumor promotion
title_full_unstemmed Key contribution of eIF4H-mediated translational control in tumor promotion
title_short Key contribution of eIF4H-mediated translational control in tumor promotion
title_sort key contribution of eif4h-mediated translational control in tumor promotion
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741870/
https://www.ncbi.nlm.nih.gov/pubmed/26498689
work_keys_str_mv AT vayssecharlotte keycontributionofeif4hmediatedtranslationalcontrolintumorpromotion
AT philippeceline keycontributionofeif4hmediatedtranslationalcontrolintumorpromotion
AT martineauyvan keycontributionofeif4hmediatedtranslationalcontrolintumorpromotion
AT quelencathy keycontributionofeif4hmediatedtranslationalcontrolintumorpromotion
AT hieblotcorinne keycontributionofeif4hmediatedtranslationalcontrolintumorpromotion
AT renaudclaire keycontributionofeif4hmediatedtranslationalcontrolintumorpromotion
AT nicaiseyvan keycontributionofeif4hmediatedtranslationalcontrolintumorpromotion
AT desquesnesaurore keycontributionofeif4hmediatedtranslationalcontrolintumorpromotion
AT pannesemaria keycontributionofeif4hmediatedtranslationalcontrolintumorpromotion
AT filleronthomas keycontributionofeif4hmediatedtranslationalcontrolintumorpromotion
AT escourroughislaine keycontributionofeif4hmediatedtranslationalcontrolintumorpromotion
AT lawsonmalcolm keycontributionofeif4hmediatedtranslationalcontrolintumorpromotion
AT rintoulrobertc keycontributionofeif4hmediatedtranslationalcontrolintumorpromotion
AT delislemariebernadette keycontributionofeif4hmediatedtranslationalcontrolintumorpromotion
AT pyronnetstephane keycontributionofeif4hmediatedtranslationalcontrolintumorpromotion
AT broussetpierre keycontributionofeif4hmediatedtranslationalcontrolintumorpromotion
AT pratsherve keycontributionofeif4hmediatedtranslationalcontrolintumorpromotion
AT touriolchristian keycontributionofeif4hmediatedtranslationalcontrolintumorpromotion